Prognostic role of long noncoding RNA CASC11 in cancer patients: A meta-analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Overexpression of cancer susceptibility candidate 11 (CASC11) is linked to poorer overall survival in various cancers. This finding suggests CASC11 may serve as a predictive biomarker for tumor progression.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Long noncoding RNA (lncRNA) regulates tumor cell proliferation, invasion, and metastasis.
- Cancer susceptibility candidate 11 (CASC11) expression correlates with cancer development and prognosis.
- CASC11 shows potential as a therapeutic target and cancer biomarker.
Purpose Of The Study
- To investigate the impact of CASC11 expression on clinicopathological features and patient outcomes.
- To evaluate CASC11 as a prognostic marker across different cancer types.
Main Methods
- A meta-analysis of 11 studies involving 660 patients.
- Searched PubMed, Embase, Web of Science, and Cochrane Library up to September 20, 2023.
- Analyzed CASC11 expression's association with overall survival (OS) and clinicopathological features using pooled hazard ratios and odds ratios with 95% confidence intervals (CI).
Main Results
- Overexpression of CASC11 was significantly associated with poor OS (HR=2.07, 95% CI=1.64-2.60).
- Consistent links between CASC11 overexpression and poorer OS were observed in digestive, respiratory, and gynecologic tumors.
- Subgroup analyses confirmed the negative prognostic value of CASC11 across diverse cancer types.
Conclusions
- CASC11 expression is strongly correlated with tumor prognosis.
- CASC11 holds potential as a predictive marker for tumor progression in multiple cancer types.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...